DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Controlling cell proliferation is one of the hallmarks of cancer. A number of critical checkpoints ascertain progression through the different stages of the cell cycle, which can be aborted when perturbed, for instance by errors in DNA replication and repair. These molecular checkpoints are regulated by a number of proteins that need to be present at the right time and quantity. The ubiquitin system has emerged as a central player controlling the fate and function of such molecules such as cyclins, oncogenes and components of the DNA repair machinery. In particular, proteases that cleave ubiquitin chains, referred to as deubiquitylating enzymes (DUBs), have attracted recent attention due to their accessibility to modulation by small molecules. In this review, we describe recent evidence of the critical role of DUBs in aspects of cell cycle checkpoint control, associated DNA repair mechanisms and regulation of transcription, representing pathways altered in cancer. Therefore, DUBs involved in these processes emerge as potentially critical targets for the treatment of not only hematological, but potentially also solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Komander, D., & Rape, M. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060310-170328 · Cited by 3,679 · cited 4×
“The process is reversible and the removal of ubiquitin is catalyzed by a subclass of isopeptidases referred to as deubiquitylating enzymes or DUBs (Hershko and Ciechanover, 1998; Komander and Rape, 2012; Mevissen et al., 2013; Swatek and Komander, 2016).”
BackgroundInfluentialRegulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.
Reyes-Turcu, F. E., Ventii, K. H., & Wilkinson, K. D. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.082307.091526 · Cited by 1,396 · cited 4×
“…deconjugating mechanisms, and because many aspects of the fundamental biology of this pathway, in particular the topology of poly ubiquitin chains and post-translational modifications present on ubiquitin itself, are not yet fully understood (Cohen and Tcherpakov, 2010; Swatek and Komander, 2016).”
BackgroundInfluentialBott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
USP10 Regulates p53 Localization and Stability by Deubiquitinating p53
Yuan, J., Luo, K., Zhang, L., Cheville, J. C., & Lou, Z. (2010) · Cell · doi:10.1016/j.cell.2009.12.032 · Cited by 637 · cited 2×
“…BRIT1 BRIT1–SWI–SNF DSB-response Ge et al., 2015 USP9X Claspin ATR-Chk1 McGarry et al., 2016 USP10 p53 and MSH2 ATM-p53 and mismatch repair (MMR) Yuan et al., 2010; Zhang et al., 2016 USP11 p53 DDR to etoposide Ke et al., 2014 USP20 Claspin ATR-Chk1 Yuan et al., 2014; Zhu et al., 2014 USP24…”
BackgroundDeubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival
Schwickart, M., Huang, X., Lill, J. R., Liu, J., Ferrando, R., French, D. M., Maecker, H., O’Rourke, K., Bazan, F., Eastham-Anderson, J., et al. (2010) · Nature · doi:10.1038/nature08646 · Cited by 628
Chauhan, D., Tian, Z., Nicholson, B., Kumar, K. G. S., Zhou, B., Carrasco, R., McDermott, J. L., Leach, C. A., Fulcinniti, M., Kodrasov, M. P., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.007 · Cited by 589 · cited 2×
“Most promisingly, the USP7 inhibitor P5091 was shown to be able to overcome Bortezomib resistance in Multiple Myeloma cells (Chauhan et al., 2012).”
BackgroundSelf-citationZhang, X.-Y., Varthi, M., Sykes, S. M., Phillips, C., Warzecha, C., Zhu, W., Wyce, A., Thorne, A. W., Berger, S. L., & McMahon, S. B. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.015 · Cited by 427 · cited 8×
“USP44 H2A and H2B DNA double-strand break response (H2A) and stem cell differentiation (H2B) Fuchs et al., 2012; Mosbech et al., 2013 USP46 H2A and H2B Xenopus development Joo et al., 2011 USP49 H2B Co-transcriptional pre-mRNA processing Zhang et al., 2013 BAP1 H2A Gene expression Scheuermann et al., 2010 OTUB1 Histon…”
InfluentialDiscovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme.
Reverdy, C., Conrath, S., Lopez, R., Planquette, C., Atmanene, C., Collura, V., Harpon, J., Battaglia, V., Vivat, V., Sippl, W., et al. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.02.007 · Cited by 270 · cited 2×
“In conclusion, all these examples are starting to point toward an emerging and important role of the DUBs in the regulation of gene expression by epigenetic events in cancer.”
BackgroundStabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.
Wang, Q., Ma, S., Song, N., Li, X., Liu, L., Yang, S., Ding, X., Shan, L., Zhou, X., Su, D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85747 · Cited by 206
Brooks, C. L., & Gu, W. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.05.022 · Cited by 186 · cited 4×
“Ring1b, Bmi1 and RNF168 p53, ATR-Chk1 and γ-H2AX (DSBs and SSBs) Brooks et al., 2007; Faustrup et al., 2009; Brooks and Gu, 2011; Alonso-de Vega et al., 2014; Qian et al., 2015; Zhu et al., 2015 USP8 BRIT1 BRIT1–SWI–SNF DSB-response Ge et al., 2015 USP9X Claspin ATR-Chk1 McGarry et al., 2016 USP10…”
BackgroundInfluential
Cited by
Mechanisms of Deubiquitinase Specificity and Regulation
Mevissen, T. E. T., & Komander, D. (2017) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-044916 · Cited by 1,027
Crosstalk Between Mammalian Autophagy and the Ubiquitin-Proteasome System
Kocaturk, N. M., & Gozuacik, D. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00128 · Cited by 419
Structure-guided development of a potent and selective non-covalent active-site inhibitor of USP7.
Lamberto, I., Liu, X., Seo, H.-S., Schauer, N. J., Iacob, R. E., Hu, W., Das, D., Mikhailova, T., Weisberg, E. L., Engen, J. R., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.003 · Cited by 192
“Not surprisingly, aberrant ubiquitin system activity is linked to disease, including cancer,(Hoeller and Dikic, 2009; Pinto-Fernandez and Kessler, 2016) infection,(Isaacson and Ploegh, 2009; Maculins et al., 2016) and neurodegeneration(Ciechanover and Brundin, 2003; Ciechanover and Kwon, 2015).”
BackgroundEmerging insights into HAUSP (USP7) in physiology, cancer and other diseases.
Bhattacharya, S., Chakraborty, D., Basu, M., & Ghosh, M. K. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0012-y · Cited by 162
“HAUSP is also related to fragile X syndrome given its stabilization of PHD finger protein 8 or Jumonji C domaincontaining histone demethylase 1F (PHF8).(45,53)”
BackgroundSelective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
Schauer, N. J., Liu, X., Magin, R. S., Doherty, L. M., Chan, W. C., Ficarro, S. B., Hu, W., Roberts, R. M., Iacob, R. E., Stolte, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-62076-x · Cited by 125
Metadata
- Authors
- Pinto-Fernandez, A., & Kessler, B. M.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2016-07-28
- Volume
- 7
- Pages
- 133-133
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W2495215685
- Cited by
- 73
- References
- 17
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets. https://app.cochat.ai/papers/10.3389/fgene.2016.00133
- The paper
- Pinto-Fernandez, A., & Kessler, B. M. (2016). DUBbing Cancer: Deubiquitylating Enzymes Involved in Epigenetics, DNA Damage and the Cell Cycle As Therapeutic Targets. Frontiers in Genetics. https://doi.org/10.3389/fgene.2016.00133
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.